DISCLAIMER: MediGuard is not intended to be a substitute for professional medical advice. MediGuard cannot and does not take into consideration every possible interaction or account for individual responses to medicine. Different individuals may respond to medication in different ways. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Always seek the advice of a qualified health provider with any questions you may have before making any changes to your treatment. The use of the MediGuard site and its content is at your own risk. The MediGuard site and the information contained in it is intended for users in the United States and information in other countries may be different.
Oxandrin is available in and 10 mg tablets. The daily adult dosage of Oxandrin is mg to 20 mg given in 2 to 4 divided doses. For children the total daily dosage of Oxandrin is less than .1 mg per kilogram body weight or less than .045 mg per pound of body weight; this drug should only be administered by specialists. Oxandrin may increase sensitivity to oral anticoagulants, and interact with oral hypoglycemic agents, adrenal steroids or ACTH. This drug should not be given during pregnancy. It is unknown if Oxandrin passes into breast milk. Oxandrin may affect milk production and it may harm a nursing infant. Breastfeeding while using Oxandrin is not recommended.
The drug was prescribed to promote muscle regrowth in disorders which cause involuntary weight loss, and is used as part of treatment for HIV/AIDS . It had also been shown to be partially successful in treating cases of osteoporosis . However, in part due to bad publicity from its illicit use by bodybuilders , production of Anavar was discontinued by Searle Laboratories in 1989. It was picked up by Bio-Technology General Corporation, which changed its name to Savient Pharmaceuticals who, following successful clinical trials in 1995, released it under the tradename Oxandrin. BTG subsequently won approvals for orphan drug status by the Food and Drug Administration (FDA) for treating alcoholic hepatitis , Turner syndrome , and HIV-induced weight loss . It is also indicated as an offset to protein catabolism caused by long-term administration of corticosteroids .